



# New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to Be Presented at Upcoming Annual Scientific Sessions of the American Heart Association

Saturday, November 03, 2007 - 10:30pm

(BUSINESS WIRE)--Pfizer announced today that new data regarding the cardiovascular and kidney function effects of Lipitor® (atorvastatin calcium) Tablets will be presented next week at the Annual Scientific Sessions of the American Heart Association.

## SPARCL Trial

A new post-hoc analysis (planned after the study completed) of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study looked at the potential kidney function effects of patients treated with Lipitor 80 mg in post-stroke patients with type 2 diabetes, metabolic syndrome and chronic kidney disease. The results of this analysis will be presented on Monday, November 5, at 9:30 a.m. EST, in the West Hall A1-A2 of the Orange County Convention Center.

## IDEAL Trial

A new post-hoc analysis (planned after the study completed) of the Incremental Decreases through Aggressive Lipid Lowering (IDEAL) clinical trial evaluated the effect of Lipitor 80 mg in reducing multiple cardiovascular events in patients with history of heart attack. The results of this analysis will be presented on Tuesday, November 6, at 11:30 a.m. EST, in Room W230cd of the Orange County Convention Center.

“These new analyses will help extend our understanding of Lipitor’s impact in patients who have experienced multiple cardiovascular events and also in post-stroke patients with type 2 diabetes, metabolic syndrome and chronic kidney disease,” said Dr. Rochelle Chaiken, vice president of Pfizer’s Cardiovascular and Metabolic Medical Division. “These post-hoc analyses come from two of the more than ten landmark trials studying the benefits of Lipitor on cardiovascular outcomes.”

## About Lipitor

Lipitor is the only statin proven to provide a combination of impressive average LDL lowering of 39 percent to 60 percent, significant and proven cardiovascular event reductions, and a well-established safety profile across a broad range of patients.

It is the most prescribed cholesterol-lowering therapy in the world, with nearly 144 million patient-years of experience. Lipitor is supported by an extensive clinical trial program involving more than 400 ongoing and completed trials with more than 80,000 patients.

## Important U.S. Prescribing Information

Lipitor is a prescription medication. It is used in patients with multiple risk factors for heart disease such as family history, high blood pressure, age, low HDL (“good” cholesterol) or smoking to reduce the risk of a heart attack and stroke, certain kinds of heart surgery and chest pain.

Lipitor is also used in patients with type 2 diabetes and at least one other risk factor for heart disease such as high blood pressure, smoking or complications of diabetes, including eye disease and protein in urine, to reduce the risk of heart attack and stroke.

Lipitor is used in patients with existing coronary heart disease to reduce the risk of heart attack, stroke, certain kinds of heart surgery, hospitalization for heart failure, and chest pain.

When diet and exercise alone are not enough, Lipitor is used along with a low-fat diet and exercise to lower cholesterol.

Lipitor is not for everyone. It is not for those with liver problems. And it is not for women who are nursing, pregnant or may become pregnant.

Patients taking Lipitor should tell their doctors if they feel any new muscle pain or weakness. This could be a sign of rare but serious muscle side effects. Patients should tell their doctors about all medications they take. This may help avoid serious drug

interactions. Doctors should do blood tests to check liver function before and during treatment and may adjust the dose. The most common side effects are gas, constipation, stomach pain and heartburn. They tend to be mild and often go away.

For additional product information, visit [www.Lipitor.com](http://www.Lipitor.com).

Pfizer IncVanessa Aristide, 212-733-3784Onsite: 917-697-0481orRebecca Hamm, 212-733-8811Onsite: 917-599-7752